Iron depletion in “metabolic fatty liver syndromes”: a strong biological rationale with disappointing liver outcomes by Amedeo Lonardo

“…Nonalcoholic fatty liver disease (NAFLD), its more rapidly progressive steatohepatitic variant [nonalcoholic steatohepatitis, (NASH)], and the recently defined metabolic dysfunction-associated fatty liver disease (MAFLD) may be collectively alluded to as “metabolic fatty liver syndromes” (MFLS). …”
Get full text

Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use? by Roxana Sirli, Ioan Sporea

“…Chronic liver diseases (CLDs) are a public health problem, even if frequently they are underdiagnosed. …”
Get full text

Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy by Parisa Shiri Aghbash, Hamed Ebrahimzadeh Leylabadlo, Hamidreza Fathi, Mohaddeseh Bahmani, Rojin Chegini, Hossein Bannazadeh Baghi

“…Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. …”
Get full text

Probiotics for Alleviating Alcoholic Liver Injury by Zelin Gu, Yanlong Liu, Shumeng Hu, Ying You, Jiaqi Wen, Wancong Li, Yuhua Wang

“…In this review, we summarize the current knowledge regarding the mechanism of action of probiotics for reducing the effects of alcoholic liver disease.…”
Get full text

Motion – The Available Treatments for Hepatitis C Are Cost Effective: Arguments against the Motion by W Ray Kim

“…Available cohortbased studies suggest that only a relative minority of patients develop significant liver disease, such as cirrhosis and/or hepatocellular carcinoma. …”
Get full text

Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis by Hiroki Nishikawa, Yukio Osaki

“…Chronic hepatitis C virus infection is the major cause of chronic liver disease. Liver cirrhosis (LC) results from different mechanisms of liver injury that lead to necroinflammation and fibrosis. …”
Get full text

A Curious Case of Iron-Deficiency Anemia by Seth Shaffer, Mayur Brahmania, Hemant Shah

“…Physical examination did not reveal any melena on digital rectal examination and there were no stigmata of chronic liver disease. Laboratory results showed hemoglobin of 47 g/L, MCV of 80 fL, and ferritin of 6 ng/mL. …”
Get full text

A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD by Newaz Hossain, Pushpjeet Kanwar, Smruti R. Mohanty

“…Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the western world with prevalence of 20–33%. …”
Get full text

Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Res... by Fan Ping, Xuan Wang, Jing Yang, Mei-cen Zhou, Wei Li, Ling-ling Xu, Yu-xiu Li

“…The RNAFH study (effect of rosuvastatin on nonalcoholic fatty liver disease in metabolic syndrome patients without overt diabetes evaluated by 1H-MRS) is a prospective randomized, single-center, open-label trail designed to assess the effect of rosuvastatin on the intrahepatocellular lipid (IHCL) level of nonalcoholic fatty liver disease (NAFLD). …”
Get full text

Short-term abstinence from alcohol and changes in cardiovascular risk factors, liver function tests and cancer-related growth factors: a prospective observational study by Gautam Mehta, Rajiv Jalan, Matteo Rosselli, James Maurice, Stewart Macdonald, Alexandra Cronberg, Tanya Khera-Butler, Colin Sumpter, Safa Al-Khatib, Anjly Jain, Christos Charalambous, Amir Gander, Cynthia Ju, Talay Hakan, Roy Sherwood, Devaki Nair, Kevin P Moore

“…Exclusion criteria were known liver disease or alcohol dependence.Primary and secondary outcome measures The primary outcome was change in insulin resistance (homeostatic model assessment (HOMA) score). …”
Get full text

Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs by Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Yanna Ma, Mingjian Zhao, Jifeng Liu, Zhijun Duan

“…Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease and is closely associated with metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome. …”
Get full text

Primary sclerosing cholangitis by Marina G Silveira, Keith D Lindor

“…Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts, resulting in end-stage liver disease and reduced life expectancy. …”
Get full text

Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis by Pascal Lapierre, Alain Lamarre

“…In both autoimmune liver disease and chronic viral hepatitis, the injury results from an immune-mediated cytotoxic T cell response to liver cells. …”
Get full text

Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis by Pooja D. Amarapurkar, Deepak N. Amarapurkar

“…As there is reduction in both anti and procoagulant factors, global tests of coagulation are normal in patients with acute and chronic liver disease indicating that coagulopathy in liver disease is more of a myth than a reality. …”
Get full text

Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea by Taehyun Yang, Juhee Ahn, Juhee Ahn, Sungho Won, Sungho Won, Sungho Won, Sanghun Lee

“…Patients with pre-existing liver disease exhibit increased susceptibility to DILI. …”
Get full text

Severe metabolic accumulation of VV116 in kidney transplant patients with impaired renal function: a case series report by Jiaying Zhang, Yuan Gao, Xiaoyun Miao, Wei Wang, Zhongkai Zhou, Yunyi Gao, Liwei Liu, Menghua Wu, Ke Ma, Ling Zhou, Yan Yang, Sha Meng, Yingmei Feng, Zhuorui Zhao, Wei Liu, Danlei Mou, Zixin Kang, Lianchun Liang, Zhongjie Hu

Get full text

Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus by Mengmeng Hu, Jingyu Yang, Beibei Gao, Zhoulu Wu, Ying Wu, Dandan Hu, Qiong Shen, Lei Chen

“…Abstract Background Formerly known as non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD) has now become the most widespread chronic liver disease worldwide. …”
Get full text

Pretransplant Evaluation and Liver Transplantation Outcome in PBC Patients by Maja Mijic, Ivona Saric, Bozena Delija, Milos Lalovac, Nikola Sobocan, Eva Radetic, Dora Martincevic, Tajana Filipec Kanizaj

“…Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic liver disease characterized by progressive cholangiocyte and bile duct destruction leading to fibrosis and finally to liver cirrhosis. …”
Get full text

Current Treatment Approaches to HCC with a Special Consideration to Transplantation by N. Bhardwaj, M. T. P. R. Perera, M. A. Silva

“…Resectable patients with early HCC and underlying liver disease are however increasingly being considered for transplantation because of potential for better disease-free survival and resolution of underlying liver disease, although this approach is limited by the availability of donor livers, especially in resectable patients. …”
Get full text

Unexplained Findings of Kayser-Fleischer-Like Rings in a Patient with Cryptogenic Cirrhosis by Mahreema Jawairia, Miral Subhani, Ghulam Siddiqui, Apsara Prasad, Ghulamullah Shahzad, Kaleem Rizvon, Paul Mustacchia

“…Nonalcoholic fatty liver disease is now recognized as the most common cause of cryptogenic cirrhosis. …”
Get full text